IL17A and in situ carcinoma: The significant effect that we observed in CIS is seemingly larger than the survival advantage seen in oesophageal cancer [44]; one possibility, therefore, is that BCG amplifies the beneficial effects associated with increased numbers of IL-17+ MCs.